dpp 4 and glp 1 together What Is Linagliptin? Linagliptin is an oral DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM) in adults. It works by blocking the enzyme DPP-4, which rapidly degrades incretin DPP-4 inhibitors in the treatment

14 Two therapeutic strategies currently exist to overcome the short half-life of incretin hormones and pharmacologically augment the incretin effect: 1) inject GLP-1 receptor agonists that are resistant to degradation by the DPP-4 enzyme and 2) orally administer DPP-4 inhibitors that delay the enzymatic degradation of naturally secreted incretin hormones ( Figure 2 )

doi: 10.1093/ajhp/62.2.173 86 GkeRFehmannHCLinnTSchmidtHKrauseMEngJet al

Semaglutide: Primarily approved for type 2 diabetes and weight management, it works by increasing insulin secretion and reducing appetite

& Daniels, G

After reaching a confluence of 8090%, the cells were treated with or without different concentrations of liraglutide (as described) for 2 h, followed by stimulation with or without IL-1 10 ng/ml for 24 h